Who is eligible for clinical trial NCT04921787?

Participants must meet protocol criteria for Substance Use Disorders. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04921787 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-04-20

EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy (NCT04921787)

🔵 Active, Not Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: Gavin Bart

🩺 Plain-English Summary (8th-Grade Level)

This study is a multi-site, cluster randomized, two group implementation trial comparing a low- versus high-intensity implementation strategy for supporting hospital-based opioid use disorder treatment (HBOT) in community hospital settings where medication for opioid use disorder (MOUD) treatment has not been implemented.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (4 items).

Location: Boston University — Boston, Massachusetts

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Be a community hospital deemed by the lead investigators to be in the region of a site/hub. Region will usually be defined as state unless a compelling case can be made as to geographic feasibility of implementing the intervention and access to relevant Medicaid data.
Be willing to identify a site champion to promote and adopt change that can address OUD in hospitalized patients.
Have hospital personnel who state that their institution is interested in and would be willing to work to implement MOUD prior to hospital discharge.
Commit to having buprenorphine-waivered prescribers willing and able to write prescriptions to bridge discharged patients to post-discharge OUD treatment, or available direct entry into outpatient MOUD with methadone or buprenorphine.
Have hospital staff who express willingness to engage with a site/hub team for training and for data collection.
Be willing to be randomized to low-intensity or high-intensity implementation support.
Provide inpatient general medical care.
Have sufficient numbers of Medicaid OUD discharges (any listed diagnosis; sufficient is defined as at least enough such that when added to the other hospitals in the region there are on average 100 discharges per year). Medicaid data must capture at least 3 discharge diagnoses, outpatient MOUD, and be available within no more than 12 months of discharge.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Have an ACS routinely prescribing MOUD at discharge.
Have an existing, functioning HBOT program or be imminently starting an HBOT initiative, as confirmed by the investigator team.
Be a Veterans Affairs hospital.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (4 Sites)

Boston University — Boston, Massachusetts
Hennepin Healthcare Research Institute — Minneapolis, Minnesota
New York University — New York, New York
Oregon Health & Science University — Portland, Oregon

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗